F S&P 500
5,203.75 -9.00 (-0.17%) F Dow Jones
39,142.00 -53.00 (-0.14%) F Nasdaq
18,144.00 -42.50 (-0.23%) E-mini Russell 2000 Index Futur
2,058.90 -5.90 (-0.29%) Petróleo
79.35 +0.36 (+0.46%) Oro
2,321.50 -0.80 (-0.03%)
Pliant Therapeutics, Inc. (PLRX)
Fuera de horario:
Pliant Therapeutics, Inc.
260 Littlefield Avenue
South San Francisco, CA 94080
United States
650 481 6770
https://pliantrx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 158
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Bernard Coulie M.B.A., M.D., Ph.D. | President, CEO & Director | 996.97k | 5.43M | 1967 |
| Dr. Keith Lamont Cummings M.B.A., M.D. | Chief Financial Officer | 684.14k | 1.69M | 1977 |
| Mr. Mike Ouimette J.D. | General Counsel & Corporate Secretary | 606.03k | 322.08k | 1973 |
| Mr. Johannes P. Hull | Chief Business Officer | 602.51k | 189.87k | 1975 |
| Dr. Éric Lefebvre M.D. | Chief Medical Officer | 734.41k | N/D | 1964 |
| Dr. Rik Derynck | Scientific Founder & Member of Scientific Advisory Board | N/D | N/D | N/D |
| Mr. Dean Sheppard M.D. | Scientific Founder & Member of Scientific Advisory Board | N/D | N/D | N/D |
| Mr. Bill DeGrado Ph.D. | Scientific Founder & Member of Scientific Advisory Board | N/D | N/D | N/D |
| Mr. Hal Chapman M.D. | Scientific Founder & Member of Scientific Advisory Board | N/D | N/D | N/D |
| Mr. Craig D. Muir | Interim Chief Technology Officer | N/D | N/D | N/D |
Descripción
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Pliant Therapeutics, Inc. a partir del 1 de mayo de 2024 es 8. Las puntuaciones principales son Auditoría: 6; Junta: 6; Derechos del accionista: 8; Compensación: 9.
